CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
panobinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01460940
NCT01460940Phase 2Completed
CompareCT.gov

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Ohio State University Comprehensive Cancer Center·interventional·Posted Oct 27, 2011·Updated Nov 14, 2017

In Brief

A Phase 2 clinical trial evaluating panobinostat and lenalidomide for Adult Lymphocyte Depletion Hodgkin Lymphoma and 5 related conditions. Completed, enrolled 24 participants across 2 sites.

Detailed Summary

This phase II trial studies how well giving panobinostat together with lenalidomide works in treating patients with relapsed or refractory Hodgkin lymphoma. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving panobinostat together with lenalidomide may be an effective treatment for Hodgkin lymphoma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
CountriesUnited States
CollaboratorsCelgene, Novartis

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 27, 2011
Enrollment StartOct 13, 2011
Primary CompletionNov 16, 2016
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 14.7 years ago

Interventions

panobinostatdrug

Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.

lenalidomidedrug

Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.